OBJECTIVES: Medication adherence is vital to disease management for patients with chronic illness. This study examined medication adherence among adult patients with selected common chronic conditions, using linked commercial claims and EHR data from 2015-2023.

METHODS: De-identified Oracle electric health record (EHR) data for ~110M patients over 139 health organizations across the US was used to identify patients aged 18-64 who were diagnosed with type 2 diabetes, asthma, migraine, anxiety disorder, or insomnia. Analysis included patients who had at least one outpatient encounter between January 1, 2015, and June 30, 2023, and had a medication prescribed at the encounter. Pharmacy claims from a nationally representative US closed claims database for ~90M EHR-linked patients from the same time period were used to determine whether prescriptions were filled. Prescriptions were considered filled if they were filled within 30 days after the encounter. Patients who filled 80% or more of their prescriptions were considered adherent. Patient-level drug adherence was compared across therapeutic areas and drug-level fill rates were compared across drug classes.

RESULTS: Among 95,980 linked diabetes patients, 45.3% were adherent. Out of 606,653 diabetes medication records, amylin analogs (73.7%) and GLP-1 receptor agonists (63.8%) had the highest fill rates, while antidiabetic combination medications (52.4%) had the lowest fill rate. Among 33,966 linked asthma patients, 45.6% were adherent. Out of 119,136 asthma medication records, leukotriene modifiers (64.8%) and methylxanthines (61.0%) had the highest fill rates, while adrenergic bronchodilators (53.3%) had the lowest fill rate. Results for migraine, anxiety disorder, and insomnia will be discussed in the poster.

CONCLUSIONS: Using EHR and claims data from nationally representative databases, low medication adherence rates were observed among linked patients with diabetes and asthma, where slightly less than half were found to have filled their prescribed medication at least 80% of the time, though adherence rates vary by medication.

ISPOR 2024

May 5-8, 2024

Posters

Clinical Outcomes

Cardiovascular Disorders (including MI, Stroke, Circulatory)

Diabetes/Endocrine/Metabolic Disorders (including obesity)

Drugs

Gastrointestinal Disorders

Genetic, Regenerative & Curative Therapies

Infectious Disease (non-vaccine)

Medical Devices

Mental Health (including addition)

Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)

Neurological Disorders

No Additional Disease & Conditions/Specialized Treatment Areas

Nutrition

Oncology

Pediatrics

Personalized & Precision Medicine

Rare & Orphan Diseases

Reproductive & Sexual Health

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Sensory System Disorders (Ear, Eye, Dental, Skin)

Surgery

Systemic Disorders/Conditions (Anesthesia

Urinary/Kidney Disorders

Economic Evaluation

Biologics & Biosimilars

Cardiovascular Disorders (including MI, Stroke, Circulatory)

Diabetes/Endocrine/Metabolic Disorders (including obesity)

Drugs

Gastrointestinal Disorders

Genetic, Regenerative & Curative Therapies

Geriatrics

Infectious Disease (non-vaccine)

Injury & Trauma

Medical Devices

Mental Health (including addition)

Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)

Neurological Disorders

No Additional Disease & Conditions/Specialized Treatment Areas

Oncology

Pediatrics

Personalized & Precision Medicine

Rare & Orphan Diseases

Reproductive & Sexual Health

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Sensory System Disorders (Ear, Eye, Dental, Skin)

Surgery

Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)

Urinary/Kidney Disorders

Vaccines

Epidemiology & Public Health

Cardiovascular Disease-ALL

Cardiovascular Disorders (including MI, Stroke, Circulatory)

Diabetes/Endocrine/Metabolic Disorders (including obesity)

Drugs

Gastrointestinal Disorders

Infectious Disease (non-vaccine)

Injury & Trauma

Medical Devices

Mental Health (including addition)

Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)

No Additional Disease & Conditions/Specialized Treatment Areas

Oncology

Pediatrics

Rare & Orphan Diseases

Reproductive & Sexual Health

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Surgery

Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)

Urinary/Kidney Disorders

Vaccines

Health Policy & Regulatory

Biologics & Biosimilars

Cardiovascular Disorders (including MI, Stroke, Circulatory)

Diabetes/Endocrine/Metabolic Disorders (including obesity)

Drugs

Generics

Genetic, Regenerative & Curative Therapies